Infectious Diseases in Obstetrics and Gynecology / 2009 / Article / Tab 2

Clinical Study

Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes

Table 2

Percent of Days with HSV-2 Viral Shedding.

Population ITTCValacyclovirPlacebo -value% Reduction
( )( )

Period 1 2527
Mean (SD %)3.0 (4.6)14.3 (16.6)
Range0–170–68

Period 2 2725
Mean (SD %)2.9 (6.5)12.6 (17.4)
Range0–290–61

Overall 5252
Mean (SD %)2.9 (5.6)13.5 (16.9) 78
Range0–290–68

ITT Period 1 3035 83
Mean (SD %)2.6 (4.3)14.9 (18.3)

Other Efficacy Parameters

ITTCValacyclovir ( )Placebo ( ) -value

Percent days with subclinical shedding, Mean (SD %)2.4 (4.8)11 (15.1) .001
Percent days with clinical shedding, Mean (SD %)0.6 (1.7)2.4 (4.4).014
Subjects with no Shedding, (%)31 (60)15 (29) .001
Proportion of subjects recurrencefree, (%)41 (79)27 (52).003
Median time to first genital herpes recurrencea (days) 6861.010

aFirst treatment period.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.